Gabather (GABA.ST)

Executive Summary

Gabather is a Swedish biopharmaceutical company specializing in next-generation therapeutics for neuropsychiatric disorders, leveraging a proprietary GABA-A receptor pharmacophore model to design novel small molecule modulators. Founded in 2014, the company aims to restore the brain's excitatory/inhibitory balance, addressing conditions such as cognitive impairment, anxiety, depression, and schizophrenia. Its lead candidate, GT-002, is a pro-cognitive GABA-A receptor modulator that has successfully completed Phase I clinical trials, demonstrating favorable safety and tolerability. Gabather's platform enables the development of subtype-selective compounds, potentially offering improved efficacy and reduced side effects compared to traditional benzodiazepines. The company is listed on the Nasdaq First North Growth Market under the ticker GABA.ST, with a current valuation of approximately $20.6 million. As Gabather progresses GT-002 into Phase II development, it also advances preclinical candidates targeting other neuropsychiatric indications. The company's focus on an underexplored but validated mechanism positions it as a potential player in the CNS space, though it remains early-stage with significant execution risk. Gabather's near-term value inflection points include the initiation of Phase II trials and potential partnership opportunities to support further development.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase II trial for GT-00270% success
• Q3 2026Presentation of full Phase I data at a scientific conference80% success
• H1 2027Announcement of strategic partnership or licensing deal40% success